Page 10 - அடித்தளம் சண்டை குருட்டுத்தன்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
streetwisereports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetwisereports.com Daily Mail and Mail on Sunday newspapers.
Share
Nathan “Nate” Light (pictured), the affable yet driven executive who helped turn Sterling Jewelers into a retail powerhouse, died on March 12 in Palm Beach, Fla. He was 86.
After serving in the U.S. Navy, Light started his industry career as a salesman at Rose Jewelers in Detroit, working for 65 cents an hour. He later became the company’s vice president of merchandising. After that, he worked as a buyer, general manager, and executive vice president at another Detroit jeweler, Shifrin-Willens.
In 1977, Light became chairman and CEO of Sterling Jewelers, in a move that proved fateful not only for his career but for the entire U.S. jewelry industry. When Light first joined the Akron, Ohio–based company, it was still a small, family-owned, 32-store chain. Under his leadership, Sterling grew to encompass 117 stores. In 1987, it was acquired by Ratners Group (now Signet), a British jeweler seeking a U.S. presence.
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
Phase 2/3 pivotal
Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2
InSight extension study to be reported in H2 2021
QR-421a
Stellar Phase 1/2 trial for Usher syndrome and non-syndromic retinitis pigmentosa interim analysis on track for late Q1/early Q2 2021
Further pipeline progress anticipated with first clinical data in 2021 from QR-1123 program for autosomal dominant retinitis pigmentosa and QR-504a clinical study in Fuchs endothelial corneal dystrophy expected to start in H1 2021
Cash runway into 2023
vimarsana © 2020. All Rights Reserved.